Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
national top stories
new york blog main
new york top stories
6
×
biotech
boston top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
biogen
clinical trials
deals
gilead sciences
indiana blog main
indiana top stories
novartis
alzheimer's disease
astrazeneca
cancer
cancer immunotherapy
covid-19
What
ceo
6
×
bio
roundup
acquisitions
drug
medicines
week
announced
big
biggest
crispr
daniel
gilead
medicine
moves
o’day
sciences
aces
aims
albert
backed
bosley's
bosley’s
bourla
bridge
bucks
build
buy
cas
cause
cholesterol
collabs
company
company’s
covid
crime
deal
debut
departure
drugs
Language
unset
unknown
Current search:
ceo
×
" new york top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More